Model-Based Dose Identification of Dalbavancin for Long-Term Suppressive Outpatient Treatment of Ventricular Assist Device Infections

MLA

Ute Chiriac, et al. “Model-Based Dose Identification of Dalbavancin for Long-Term Suppressive Outpatient Treatment of Ventricular Assist Device Infections.” Antibiotics, vol. 13, no. 11, Nov. 2024, p. 1103. EBSCOhost, https://doi.org/10.3390/antibiotics13111103.

APA

Ute Chiriac, Uwe Liebchen, Otto Roman Frey, Heike Lanzinger, Sabrina Klein, Torsten Hoppe-Tichy, Matthias Karck, Anna Meyer, & Benedict Morath. (2024). Model-Based Dose Identification of Dalbavancin for Long-Term Suppressive Outpatient Treatment of Ventricular Assist Device Infections. Antibiotics, 13(11), 1103. https://doi.org/10.3390/antibiotics13111103

Chicago

Ute Chiriac, Uwe Liebchen, Otto Roman Frey, Heike Lanzinger, Sabrina Klein, Torsten Hoppe-Tichy, Matthias Karck, Anna Meyer, and Benedict Morath. 2024. “Model-Based Dose Identification of Dalbavancin for Long-Term Suppressive Outpatient Treatment of Ventricular Assist Device Infections.” Antibiotics 13 (11): 1103. doi:10.3390/antibiotics13111103.